The main aim of this study was to investigate the risk of prostate cancer metastasis formation associated with the expression of ETS homologous factor (EHF) in a cohort of bioptic samples. To this end, the expression of EHF was evaluated in a cohort of 152 prostate biopsies including primary prostate cancers that developed metastatic lesions, primary prostate cancers that did not develop metastasis, and benign lesions. Data here reported EHF as a candidate immunohistochemical prognostic biomarker for prostate cancer metastasis formation regardless of the Gleason scoring system. Indeed, our data clearly show that primary lesions with EHF positive cells ≥40% had a great risk of developing metastasis within five years from the first diagnosis. Patients with these lesions had about a 40-fold increased risk of developing metastasis as compared with patients with prostate lesions characterized by a percentage of EHF positive cells ≤30%. In conclusion, the immunohistochemical evaluation of EHF could significantly improve the management of prostate cancer patients by optimizing the diagnostic and therapeutic health procedures and, more important, ameliorating the patient's quality of life.

Scimeca, M., Montanaro, M., Bonfiglio, R., Anemona, L., FINAZZI AGRO', E., D Asimakopoulos, A., et al. (2022). The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. DIAGNOSTICS [10.3390/diagnostics12040800].

The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis.

Manuel Scimeca
;
Rita Bonfiglio;Lucia Anemona;Enrico Finazzi Agrò;Roberto Bei;Vittorio Manzari;Erica Giacobbi;Francesca Servadei;Elena Bonanno;Orazio Schillaci;Alessandro Mauriello.
2022-03-24

Abstract

The main aim of this study was to investigate the risk of prostate cancer metastasis formation associated with the expression of ETS homologous factor (EHF) in a cohort of bioptic samples. To this end, the expression of EHF was evaluated in a cohort of 152 prostate biopsies including primary prostate cancers that developed metastatic lesions, primary prostate cancers that did not develop metastasis, and benign lesions. Data here reported EHF as a candidate immunohistochemical prognostic biomarker for prostate cancer metastasis formation regardless of the Gleason scoring system. Indeed, our data clearly show that primary lesions with EHF positive cells ≥40% had a great risk of developing metastasis within five years from the first diagnosis. Patients with these lesions had about a 40-fold increased risk of developing metastasis as compared with patients with prostate lesions characterized by a percentage of EHF positive cells ≤30%. In conclusion, the immunohistochemical evaluation of EHF could significantly improve the management of prostate cancer patients by optimizing the diagnostic and therapeutic health procedures and, more important, ameliorating the patient's quality of life.
24-mar-2022
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/46 - SCIENZE TECNICHE DI MEDICINA E DI LABORATORIO
Settore MED/08 - ANATOMIA PATOLOGICA
Settore MED/04 - PATOLOGIA GENERALE
Settore MED/24 - UROLOGIA
English
Con Impact Factor ISI
prostate cancer, ETS homologous factor, metastasis, histological marker
Scimeca, M., Montanaro, M., Bonfiglio, R., Anemona, L., FINAZZI AGRO', E., D Asimakopoulos, A., et al. (2022). The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. DIAGNOSTICS [10.3390/diagnostics12040800].
Scimeca, M; Montanaro, M; Bonfiglio, R; Anemona, L; FINAZZI AGRO', E; D Asimakopoulos, A; Bei, R; Manzari, V; Urbano, N; Giacobbi, E; Servadei, F; Bonanno, E; Schillaci, O; Mauriello, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
diagnostics-12-00800 (3).pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 9.7 MB
Formato Adobe PDF
9.7 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/299426
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact